MedTrace Logo

The Establishment of a Survival Prediction Model for ER Positive / HER-2 Negative Advanced Breast Cancer

NCT04683757 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 288

Last updated 2020-12-24

No results posted yet for this study

Summary

This project is a prospective, clinical cohort study initiated by researchers to study the high-risk factors affecting the overall survival of newly diagnosed ER + / HER2 - advanced breast cancer patients and to establish a prediction model of ER + / HER2 - advanced breast cancer patients affecting overall survival. This project is the first prospective prediction model for the survival of patients with advanced breast cancer, and it is also the first time to establish a survival prediction model for ER-positive / HER2 negative advanced breast cancer suitable for China's national conditions. According to the survival outcome predicted by the model, the newly diagnosed ER positive / HER2 negative advanced breast cancer was divided into three groups: low, medium, and high risk, which provided an important theoretical basis for further design of randomized controlled clinical research and guidance of individualized precise treatment scheme for different groups in the future.

Conditions

Interventions

OTHER

Establishment of a Survival Prediction Model

a nomogram to predict the survival of patients with ER positive / HER-2 negative advanced breast cancer

Sponsors & Collaborators

  • Ying Wang

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2021-01-01
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04683757 on ClinicalTrials.gov